Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of F901318 and Fluconazole in Healthy Volunteers
NCT02730442Phase 1Completed
- Sponsor
- F2G
- Start
- Feb 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olorofim in invasive aspergillosis (IA) (3 arms), sponsored by F2G. Primary endpoint: Treatment Emergent Adverse Events at 5 days. Started Feb 2016; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02730442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730442.